New funding for glaucoma research

Article

Fight for Sight, a UK leading eye research charity, has awarded two new grants totalling £350,000 for research into glaucoma ? one of the leading causes of preventable blindness in the UK

Fight for Sight, a UK leading eye research charity, has awarded two new grants totalling £350,000 for research into glaucoma – one of the leading causes of preventable blindness in the UK.

Glaucoma affects 1 in 50 people over the age of 40 in the UK and yet half of people affected are unaware of their condition.

National Glaucoma Awareness Week in the early part of June highlighted the importance of regular eye tests for detecting glaucoma in its early stages.

Dr Forbes Manson at The University of Manchester has been awarded a grant of £151,442 to support his research into the causes of primary open angle glaucoma (POAG) – one of the most common forms of the condition.

In POAG, increased pressure causes damage to the cells at the back of the eye often leading to permanent blindness: “The identification of a new POAG gene will be a major step forward and will enable the early detection and treatment of individuals likely to develop the disease, which is vital for avoiding permanent blindness,” said Dr Manson.

Dr Barbara Lorber at the University of Cambridge has been awarded a grant of £199,971 through the Fight for Sight Early Career Investigator Award which is helping young researchers to progress their career in vision research.

Dr Lorber will look at transplanting specialist cells into the eye and optic nerve to repair the damage caused by glaucoma. She said: “Harnessing the positive potential of these specialist retinal cells may open up new avenues in the treatment of glaucoma.”

Michèle Acton, Fight for Sight chief executive, said: “Glaucoma is the second most common cause of sight loss worldwide. By funding new research into the causes of this serious condition and supporting the development of new treatments we are offering real hope to the huge number of people affected by glaucoma.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.